CAS: 14882-18-9; 2-Hydroxy-4H-Benzo[d][1,3,2]Dioxabismin-4-One

该化合物是一种该化合物是一种抗酸性,抗炎和温性抗微生物剂,能够有效地治疗腹泻,消化和心脏灼伤等病症.该化合物通过涂层胃衬垫,提供防刺激剂的屏障,而其盐酸成分会减少炎症.乙酰亚硅酸盐还表现出抗菌活动,可以对抗Helcobacter pylori等病原体.其低系统吸收会最大限度地减少副作用,确保病人安全.该化合物在标准条件下稳定,并配制成片片,悬浮或口腔管理可嚼的形式.其多功能和功效使它成为广泛使用的抗药剂.

结构式图片

欧盟法规

REACH注册C&L通报REACH预注册

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-7211590-B2
    优先权日:2002-08-01
    标 题:Nitrosated proton pump inhibitors, compositions and methods of use
    发明人:FANG XINQIN; GARVEY DAVID S; LETTS L GORDON
    权利人:NITROMED INC
    摘要:The invention describes novel nitrosated proton pump inhibitor compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated proton pump inhibitor compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated proton pump inhibitor compound, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated proton pump inhibitor compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating gastrointestinal disorders; facilitating ulcer healing; decreasing the recurrence of ulcers; improving gastroprotective properties, anti-Helicobacter pylori properties or antacid properties of proton pump inhibitors; decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds; treating bacterial infections and/or viral infections.

    专利号:US-7256205-B2
    优先权日:1998-11-17
    标题 :Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use
    发明人:GARVEY DAVID S; LETTS L GORDON; LIN CHIA-EN; WANG TIANSHENG
    权利人:NITROMED INC
    摘要:The invention describes novel nitrosated and/or nitrosylated H 2 receptor antagonist compounds, and novel compositions comprising at least one H 2 receptor antagonist compound that is optionally substituted with at least one NO and/or NO 2 group, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase and/or at least one nonsteroidal antiinflammatory drug, antacid, bismuth-containing reagent or anti-viral agent. The invention also describes methods for treating and/or preventing gastrointestinal disorders; improving gastroprotective properties of H 2 receptor antagonists; decreasing the recurrence of ulcers; facilitating ulcer healing; preventing and/or treating inflammations and microbial infections, ophthalmic diseases and disorders, multiple sclerosis, and viral infections; and decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds.

    专利号:US-7332505-B2
    优先权日:1999-02-26
    标 题 :Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use
    发明人:GARVEY DAVID S; LETTS L GORDON; RICHARDSON STEWART K; TAM SANG WILLIAM; WANG TIANSHENG
    权利人:NITROMED INC
    摘要:The present invention describes novel nitrosated and/or nitrosylated proton pump inhibitor compounds, and novel compositions comprising at least one proton pump inhibitor compound that is optionally substituted with at least one NO and/or NO 2 group, and, optionally, at least one compound that donates, transfers, or releases nitric oxide, induces the production of endogenous nitric oxide or endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one nonsteroidal antiinflammatory drug, selective COX-2 inhibitor, antacid, bismuth-containing reagent, acid-degradable antibacterial compound, and mixtures thereof. The present invention also provides methods for treating and/or preventing gastrointestinal disorders; facilitating ulcer healing; decreasing the recurrence of ulcers; improving gastroprotective properties, anti- Helicobacter pylon properties or antacid properties of proton pump inhibitors; decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds; treating Helicobacter pylori and viral infections. The compounds and/or compositions of the present invention can also be provided in the form of a pharmaceutical kit.

    专利号:US-5639987-A
    优先权日:1994-11-29
    标题:Compositions modifying ballistic properties and propellants containing such compositions
    发明人:BERTELEAU GERARD; FONBLANC GILLES; LONGEVIALLE YVES; RAT MAURICETTE
    权利人:POUDRES & EXPLOSIFS STE NALE
    摘要:The present invention lies in the field of compositions which modify the ballistic properties of solid propellants and in that of the double-base solid propellants containing these compositions. Various lead compounds are known to be effective in this function, but these compounds are toxic; the problem which is solved by the present invention is to replace these lead compounds with nontoxic compounds which furthermore do not impair other properties and the performance values of the propellants. The modifying compounds are chosen from the group consisting of beta -resorcylates and gamma -resorcylates. The invention also relates to processes for the synthesis of some of these products. Finally, it relates to double-base solid propellants containing these compounds.

    专利号:RU-2130933-C1
    优先权日:1992-10-27
    标题 :Derivatives of 4-quinolinyl showing anti-helicobacterial activity, method of their synthesis, pharmaceutical composition containing their and method of its preparing
    浙江新明珠药业有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.mz-bk.com
    电话: 0086 579 82207761👤
    📞浙江新明珠药业有限公司 ⚠️参考联系方式

    销售电话:0086 579 82207761
    邮箱:sst33@163.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:浙江省金华市金磐开发区新区深泽路169号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    江苏苏中药业集团股份有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.suzhongyy.com
    电话: 0523-88851180👤
    📞江苏苏中药业集团股份有限公司 ⚠️参考联系方式

    销售电话:0523-88851180
    邮箱:scb@szyy.cn
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:江苏省姜堰市苏中路1号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    湖北猫尔沃生物医药有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.marvel-bio.com
    企业联系电话:15387162023👤
    📞湖北猫尔沃生物医药有限公司 ⚠️参考联系方式
    联系人:宋经理
    电话:15387162023
    手机:15387162023
    传真:027-877288767
    邮箱:1824363398@qq.com
    通信地址: 湖北省高新技术开发区关山大道
    邮编: 430070
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:湖北省高新技术开发区关山大道
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    武汉华玖医药科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.whhjpharm.com
    企业联系电话:18120446293👤
    📞武汉华玖医药科技有限公司 ⚠️参考联系方式
    联系人:汪经理
    电话:18120446293
    手机:18120446293
    传真:027-59220200
    邮箱:3504472216@qq.com
    通信地址: 武汉市东西湖区泾河办事处陈家岭189号
    邮编: 432000
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:武汉市东西湖区泾河办事处陈家岭189号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Pitz AM, Park GW, Lee D, Boissy YL, Vinjé J. Antimicrobial activity of bismuth subsalicylate on Clostridium difficile, Escherichia coli O157:H7, norovirus, and other common enteric pathogens. Gut Microbes. 2015;6(2):93-100. doi: 10.1080/19490976.2015.1008336.
    2: Hinostroza Morales D, Díaz Ferrer J. [Addition of bismuth subsalicylate to triple eradication therapy for Helicobacter pylori infection: efficiency and adverse events]. Rev Gastroenterol Peru. 2014 Oct-Dec;34(4):315-20. Spanish. doi: 10.1179/2047773215Y.0000000028. Epub 2015 Aug 11.
    4: Bingham AL, Brown RO, Dickerson RN. Inadvertent exaggerated anticoagulation following use of bismuth subsalicylate in an enterally fed patient receiving warfarin therapy. Nutr Clin Pract. 2013 Dec;28(6):766-9. doi: 10.1177/0884533613507606. Epub 2013 Oct 25. doi: 10.14309/crj.2014.27. eCollection 2014 Apr.

    合成参考文献


    摘要:Journal of Chemotherapy., 10(77), 1934
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知